TITLE

Camptocormia in Parkinson's disease: new insights

AUTHOR(S)
Djaldetti, R.; Melamed, E.
PUB. DATE
November 2006
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Nov2006, Vol. 77 Issue 11, p1205
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers insights on camptocormia in Parkinson's disease. Camptocormia has just been recently known as one of the extreme posture impairments in patients with Parkinson's disease. Although early reports often attributed this symptom to a conversion disorder or malingering, it is now accepted as one of the axial features of Parkinson's disease. Camptocormia is defined by marked anteroflexion of the trunk, which abates the recumbent position, with no or minimal response to levodopa.
ACCESSION #
23093956

 

Related Articles

  • Tolcapone: a review of its use in the management of Parkinson's disease. Keating, Gillian M.; Lyseng-Williamson, Katherine A. // CNS Drugs;2005, Vol. 19 Issue 2, p165 

    Tolcapone (Tasmar) is a selective, reversible inhibitor of peripheral and central catechol-O-methyltransferase (COMT). Results of well designed studies indicate that oral tolcapone is an effective adjunct to levodopa plus a peripheral dopa-decarboxylase inhibitor (DDCI) in patients with...

  • Parkinson's Disease.  // Parkinson's Disease Fact Sheet;2010, p1 

    The article presents information on Parkinson's disease (PD), a neurodegenerative disease in which the brain cells progressively die. Tremor, rigidity, extreme slowness of movement and impaired balance are some of the symptoms of the disease. Levodopa is the drug of choice for the disease. It is...

  • Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson’s patients. Stocchi, F.; Barbato, L.; Nordera, G.; Bolner, A.; Caraceni, T. // Journal of Neural Transmission;Feb2004, Vol. 111 Issue 2, p173 

    Summary. The aim of this trial was to evaluate the effects of the COMT inhibitor entacapone on both the pharmacokinetic profile and clinical efficacy of controlled release levodopa in Parkinson’s disease (PD) patients. Twelve PD patients experiencing ‘end-of-dose’ type motor...

  • A paradoxical acute effect of levodopa in de novo parkinsonian patients: worsening of some bradykinetic components. Pasetti, C.; Lualdi, M. M.; Pinelli, P. // Neurological Sciences;Oct2003, Vol. 24 Issue 3, p201 

    Reports of alterations of reaction times (RTs) in Parkinson's disease are often discordant, particularly when the aim of the research is investigation of the relationship between levodopa (LD) administration and RTs. Slowing of simple RT in a group of de novo parkinsonian patients 3 0-90 mm...

  • Verbal and visual memory in patients with early Parkinson's disease: Effect of levodopa. Singh, Sumit; Behari, Madhuri // Neurology India;Mar2006, Vol. 54 Issue 1, p33 

    Background: The effect of initiation of levodopa therapy on the memory functions in patients with Parkinson's disease remains poorly understood. Aims: To evaluate the effect of initiation of levodopa therapy on memory, in patients with early Parkinson's disease. Settings and Design: Prospective...

  • Modulation of Habit Formation by Levodopa in Parkinson's Disease. Marzinzik, Frank; Wotka, Johann; Wahl, Michael; Krugel, Lea K.; Kordsachia, Catarina; Klostermann, Fabian // PLoS ONE;2011, Vol. 6 Issue 11, p1 

    Dopamine promotes the execution of positively reinforced actions, but its role for the formation of behaviour when feedback is unavailable remains open. To study this issue, the performance of treated/untreated patients with Parkinson's disease and controls was analysed in an implicit learning...

  • Gender effect on time to levodopa-induced dyskinesias. Hassin-Baer, Sharon; Molchadski, Irena; Cohen, Oren; Nitzan, Zeev; Efrati, Lilach; Tunkel, Olga; Kozlova, Evgenia; Korczyn, Amos // Journal of Neurology;Nov2011, Vol. 258 Issue 11, p2048 

    Levodopa-induced dyskinesias (LID) are commonly observed during long-term treatment of patients with Parkinson's disease (PD). The impact of non-pharmacological factors on the latency to LID appearance is not known. The aim of the paper was to identify factors associated with time to appearance...

  • Levodopa in Parkinson's Disease: Neurotoxicity Issue Laid to Rest? Murer, M.G.; Raisman-Vozari, R.; Gershanik, O. // Drug Safety;Nov1999, Vol. 21 Issue 5, p339 

    Orally administered levodopa remains the most effective symptomatic treatment for Parkinson's disease. The introduction of levodopa therapy is often delayed, however, because of the fear that it might be toxic for the remaining dopaminergic neurons, and thus accelerate the deterioration of the...

  • Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off. Kuoppamäki, Mikko; Leinonen, Mika; Poewe, Werner // Journal of Neural Transmission;Dec2015, Vol. 122 Issue 12, p1709 

    Entacapone is frequently used together with levodopa/carbidopa (LC) and levodopa/benserazide (LB) in the treatment of Parkinson's disease (PD) patients with wearing-off symptoms. It is generally assumed that the effects of entacapone are independent of the type of decarboxylase inhibitor used,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics